PubRank

Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer

Clinical Trial ID NCT02963090

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02963090

Top papers

Rank Title Journal Year PubWeight™‹?›
1 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009 77.71
2 The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012 24.94
3 Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009 24.11
4 Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002 23.42
5 Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013 20.16
6 A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2009 18.39
7 Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014 16.83
8 Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015 11.89
9 Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015 10.12
10 Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014 8.63
11 Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012 7.76
12 The B7-CD28 superfamily. Nat Rev Immunol 2002 7.24
13 Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014 6.88
14 Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012 5.28
15 Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013 5.23
16 Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012 4.70
17 SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004 4.58
18 NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 2008 4.53
19 Exploiting the mutanome for tumor vaccination. Cancer Res 2012 4.45
20 Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012 4.44
21 Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999 3.48
22 PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A 2001 3.32
23 Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics 2008 2.69
24 Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 2007 2.26
25 The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 2005 2.22
26 Comprehensive genomic profiles of small cell lung cancer. Nature 2015 2.20
27 Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997 2.19
28 Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell 2013 2.18
29 Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2012 2.14
30 Immune regulation of cancer. J Clin Oncol 2010 1.99
31 PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer 2015 1.85
32 Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nat Protoc 2012 1.76
33 Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 2004 1.70
34 Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007 1.67
35 Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol 2009 1.66
36 Small-cell lung cancers in patients who never smoked cigarettes. J Thorac Oncol 2014 1.60
37 Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997 1.47
38 Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice. Proc Natl Acad Sci U S A 2003 1.39
39 PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion. Eur J Immunol 2005 1.18
40 Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res 2008 1.09
41 Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer. Eur Respir J 2006 1.06
42 Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. J Pathol 1999 1.01
43 Small-cell lung cancer: prognostic factors and changing treatment over 15 years. Clin Lung Cancer 2011 0.92
44 Recent advances with topotecan in the treatment of lung cancer. Oncologist 2007 0.89
45 High sensitivity to peripheral blood lymphocytes and low HLA-class I antigen expression of small cell lung cancer cell lines with diverse chemo-radiosensitivity. Jpn J Cancer Res 1992 0.79
46 Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function. Int Immunol 2007 0.76
Next 100